In this paper, our findings demonstrated that ADSCs enhance VEGFR3-mediated lymphangiogenesis via METTL3-mediated VEGF-C m6A modification to improve wound healing of diabetic foot ulcers, indicating that ADSCs can be applied for the clinical treatment of DFU. Here, METTL3 is linked to diabetic foot.